Since the launch of its revolutionary weight-loss drug Wegovy in 2021, Novo Nordisk $NVO has outperformed its pharmaceutical peers, rapidly becoming Europe’s most valuable publicly traded company. At its peak, Novo Nordisk boasted a market capitalization of $615 billion, drawing substantial attention from both the broader market and healthcare industry.